Scribe Therapeutics
Update in progressSCTX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing genetic medicines using CRISPR-based tools to address root causes of disease, with emphasis on cardiometabolic conditions in the United States. Programs include STX-1150 for in vivo epigenetic silencing of PCSK9, STX-1200 a CRISPR gene-editing program for elevated Lp(a), and STX-1400 targeting APOC3 mRNA. Uses ELXR for durable silencing and XE for precise editing. Founded 2017, based in Alameda, California.
Company score
- Sentiment
- 0.48
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.29
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.28
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!